RC98 / Rongchang Pharma - LARVOL DELTA

Preclinical Pharmacokinetics and Pharmacology Study of RC98: A Programmed Cell Death Ligand 1 Monoclonal Antibody in Cynomolgus Monkeys. (PubMed, Curr Pharm Des) - "These data indicate that the immune system was clearly activated. In addition, the non-clinical data could provide a basis for its efficacy evaluation in clinical trials."

Journal • PK/PD data • Preclinical • Oncology • CD8 • PD-L1

To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG) (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: RemeGen Co., Ltd. | Trial primary completion date: Dec 2023 ➔ May 2024

Metastases • Trial primary completion date • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor • HER-2

A Study of RC98 in Subjects With Advanced Malignant Solid Tumors (clinicaltrials.gov) - P1 | N=63 | Active, not recruiting | Sponsor: RemeGen Co., Ltd. | Recruiting ➔ Active, not recruiting | N=25 ➔ 63

Enrollment change • Enrollment closed • Gastrointestinal Cancer • Oncology • Solid Tumor

To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG) (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: RemeGen Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor • HER-2

To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Veldicitumab Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG) (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: RemeGen Co., Ltd.

New P1 trial • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor • HER-2

A Study of RC98 in Subjects With Advanced Malignant Solid Tumors (clinicaltrials.gov) - P1 | N=25 | Recruiting | Sponsor: RemeGen Co., Ltd. | Trial completion date: Mar 2022 ➔ Dec 2023 | Trial primary completion date: Dec 2021 ➔ Dec 2022

Trial completion date • Trial primary completion date • Gastrointestinal Cancer • Oncology • Solid Tumor

A Study of RC98 in Subjects With Advanced Malignant Solid Tumors (clinicaltrials.gov) - P1; N=25; Recruiting; Sponsor: RemeGen Co., Ltd.; Trial completion date: Nov 2021 ➔ Mar 2022; Trial primary completion date: Aug 2021 ➔ Dec 2021

Clinical • Trial completion date • Trial primary completion date • Gastrointestinal Cancer • Oncology • Solid Tumor

A Study of RC98 in Subjects With Advanced Malignant Solid Tumors (clinicaltrials.gov) - P1; N=25; Recruiting; Sponsor: RemeGen; Not yet recruiting ➔ Recruiting; Trial completion date: Apr 2021 ➔ Nov 2021; Trial primary completion date: Feb 2021 ➔ Aug 2021

Clinical • Enrollment open • Trial completion date • Trial primary completion date • Gastrointestinal Cancer • Oncology • Solid Tumor

Newly added product (clinicaltrials.gov) - P1, Oncology

Pipeline update